← All indications
Invasive Fungal Infections
Mycoses which manifest as infections of deep tissue or blood.
Subtype terms (4)
More specific conditions that are subtypes of Invasive Fungal Infections in the MeSH hierarchy.
- Candidiasis, Invasive
18 drugs (14 approved, 4 experimental)
- Fungemia
12 drugs (10 approved, 2 experimental)
- Invasive Pulmonary Aspergillosis
9 drugs (7 approved, 2 experimental)
- Neuroaspergillosis
2 drugs approved
Drugs by status
Phase 4 trials (9)
Phase 3 trials (1)
Phase 1 trials (3)
Organizations
Organization Involved with Phase 4 Indications (21)
- Astellas
- Schering-Plough
- Merck
- Pfizer
- National Institute of Allergy and Infectious Diseases (NIAID)
- University of Pittsburgh
- Cornell University
- European Group for Blood and Marrow Transplantation
- Katholieke Universiteit Leuven
- Melbourne Health
- Radboud University
- Universidad Autonoma de Madrid
- Wenzhou Medical University
- Zhejiang Chinese Medical University
- University of Ulsan
- Zhejiang University
- Jiao Tong University
- St. Antonius Hospital, Nieuwegein
- Janssen Pharmaceutica NV
- Sungkyunkwan University
- Shantou University
Organization Involved with Phase 3 Indications (20)
- Basilea Pharmaceutica
- Enzon
- Gilead Sciences
- Medical Research Council
- National Cancer Institute (NCI)
- Meander Medical Center
- Seoul National University
- University of Groningen
- Utrecht University
- Yonsei University
- Cardiff University
- Daegu Catholic University
- Leiden University
- University of Amsterdam
- Free University of Amsterdam
- Cidara Therapeutics
- University of Texas at Houston
- Erasmus University Rotterdam
- Klinikum Oldenburg
- Haga Hospital, Leyweg
Organization Involved with Phase 2 Indications (13)
Organization Involved with Phase 1 Indications (4)
Organization Involved with Other Experimental Indications (3)